The Future of Biosimilar Insulins

Diabetes Spectrum - United States
doi 10.2337/diaspect.29.3.161
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Diabetes Association

Related search

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2015English

Diabetes I: Insulins.

BMJ
1983English

Duration of the Action of Different Insulins

BMJ
1952English

Pms73 - Bright Future for the Use of Biosimilar Infliximab: Evidence-Based Analysis Using Healthcare Claim Database

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Conformation of Insulin-Like Growth Factors: Relationships With Insulins

Journal of Cell Science
Cell Biology
1985English

New Insulins, Biosimilars, and Insulin Therapy

Diabetes Technology and Therapeutics
MedicineEndocrinologyMedical Laboratory TechnologyMetabolismDiabetes
2020English

Protamine and Protamine-Insulins Exacerbate the Vascular Response to Injury.

Journal of Clinical Investigation
Medicine
1993English

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2014English

GP2015: An Etanercept Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy